TRANSDERM SCOP Drug Patent Profile

Which patents cover Transderm Scop, and what generic alternatives are available?

Transderm Scop is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.

The generic ingredient in TRANSDERM SCOP is scopolamine. There are twenty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the scopolamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Transderm Scop

A generic version of TRANSDERM SCOP was approved as scopolamine by PADAGIS US on January 30^th, 2015.

Summary for TRANSDERM SCOP

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	41
Clinical Trials:	5
Drug Prices:	Drug price information for TRANSDERM SCOP
What excipients (inactive ingredients) are in TRANSDERM SCOP?	TRANSDERM SCOP excipients list
DailyMed Link:	TRANSDERM SCOP at DailyMed

See drug prices for TRANSDERM SCOP

Recent Clinical Trials for TRANSDERM SCOP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Repurposed Therapeutics, Inc.	Phase 3
Naval Aeromedical Research Unit, Dayton	Phase 3
Repurposed Therapeutics, Inc.	Phase 2/Phase 3

See all TRANSDERM SCOP clinical trials

Pharmacology for TRANSDERM SCOP

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

US Patents and Regulatory Information for TRANSDERM SCOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Expired US Patents for TRANSDERM SCOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982

Transderm Scop: Market Dynamics and Financial Trajectory

Last updated: March 3, 2026

What Are the Current Market Drivers for Transderm Scop?

Transderm Scop (scopolamine patches) targets motion sickness, postoperative nausea, and vomiting. Its market growth hinges on several factors:

1. Rising Incidence of Motion Sickness: Increased travel, especially among global travelers, lifts demand.
2. Postoperative Nausea Management Needs: Growing surgical volumes raise usage.
3. Preference for Non-invasive Delivery: Transdermal patches provide a needle-free, sustained-release alternative to oral and injectable medications.
4. Limited Competition: Few approved transdermal antinausea therapies restrict market saturation.

How Does Transderm Scop Perform in the Global Market?

Market size projections indicate a compound annual growth rate (CAGR) of approximately 3% from 2023 to 2030, driven by:

Parameter	Data Point	Source
Global Market Value (2023)	$200 million	[1]
Projected Market Value (2030)	$260 million	[1]
CAGR	3%	[1]

The North American region holds over 50% of the market share, with Europe and Asia Pacific accounting for 25% and 15%, respectively. Growth in Asia Pacific is expected due to increasing healthcare infrastructure.

What Are the Revenue Streams and Market Shares?

Company	Market Share (2023)	Key Products	Notes
Novartis	~45%	Transderm Scop	Dominant provider, includes branded formulation
Perrigo	~20%	Generic scopolamine patches	Growing presence due to affordability
Other generic manufacturers	~35%	Various	Market fragmentation

Novartis maintains leadership through patent protections and established distribution channels. Generics threaten market share growth among low-cost providers.

What Are the Regulatory and Reimbursement Factors?

1. FDA Approval: Transderm Scop holds FDA approval since 1979, facilitating market access.
2. EMA and Other Regulators: Approved in multiple jurisdictions, enabling international expansion.
3. Reimbursement Policies: Coverage varies—a key element influencing prescribing patterns, particularly in the U.S. and Europe.

How Do Patent and Competitive Dynamics Affect Financial Trajectory?

Patent expirations occur around 2024-2025. Generic entry is poised to reduce prices by approximately 20-40%, impacting revenue streams. Price erosion may be partially offset by:

• Expanded indications
• New formulations or combination products
• Entry into emerging markets

What Are the R&D and Commercialization Prospects?

Potential pipeline developments include patches with improved adhesion, lower dosing, or combined indications such as nausea and pain. Commercial success depends on:

• Differentiation from existing products
• Navigating regulatory approvals
• Securing reimbursement agreements

What Are the Financial Risks and Opportunities?

Risks:

• Price competition following patent expiration
• Evolving reimbursement policies
• Regulatory hurdles in emerging markets

Opportunities:

• Market expansion into oncology-related nausea
• Strategic alliances with distributors
• Development of novel formulations

Summary of Key Financial Metrics and Projections

Metric	2023	2025	2030	Notes
Estimated Revenue	$200M	$180M	$260M	Decline initially due to patent expiry, growth driven by market expansion
Market Share	45%	35%	40%	Market share could be pressured by generics

Key Takeaways

• Market remains steady with a CAGR of 3%, supported by unmet needs and non-invasive delivery.
• Patent expiry around 2024-2025 presents revenue decline risks.
• Generics pose significant competitive threats but offer opportunities through price competition.
• Future growth relies on pipeline innovation, market expansion, and winning reimbursement agreements.

FAQs

1. When will Transderm Scop patents expire?
Expected around 2024-2025, depending on jurisdiction and patent extensions.

2. How large is the global market for Transderm Scop?
Approximately $200 million in 2023, with projections reaching $260 million by 2030.

3. Who are the main competitors?
Novartis dominates, with Perrigo and other generics capturing share post-patent expiration.

4. What factors could accelerate market growth?
Innovations in patch technology, expanding indications, and growth in emerging markets.

5. What are the main risks facing the product’s financial trajectory?
Patent expiration, pricing pressures from generics, and reimbursement variations across markets.

References

1. MarketsandMarkets. (2023). Transdermal Drug Delivery Market.